Recent in vitro and in vivo studies highlight the strong potential of dimethyl trisulfide (DMTS) as an antidote for cyanide (CN) intoxication. Due to its high oxygen demand, the brain is one of the main target organs of CN. The blood-brain barrier (BBB) regulates the uptake of molecules into the brain. In the literature, there is no data about the ability of DMTS to penetrate the BBB. Therefore, our aim was to test the in vitro BBB penetration of DMTS and its in vivo pharmacokinetics in blood and brain. The in vitro BBB penetration of DMTS was measured by using a parallel artificial membrane permeability assay (BBB-PAMPA), and a triple BBB co-culture model. The pharmacokinetics was investigated in a mouse model by following the DMTS concentration in blood and brain at regular time intervals following intramuscular administration. DMTS showed high penetrability in both in vitro systems (apparent permeability coefficients: BBB-PAMPA 11.8 Â 10 À6 cm/s; cell culture 158 Â 10 À6 cm/s) without causing cell toxicity and leaving the cellular barrier intact. DMTS immediately absorbed into the blood after the intramuscular injection (5 min), and rapidly penetrated the brain of mice (10 min). In addition to the observed passive diffusion in the in vitro studies, the contribution of facilitated and/or active transport to the measured high permeability of DMTS in the pharmacokinetic studies can be hypothesized. Earlier investigations demonstrating the antidotal efficacy of DMTS against CN together with the present results highlight the promise of DMTS as a brain-protective CN antidote.
thiocyanate, the efficacy of these enzymes are limited (Wrobel et al., 2004) . The brain contains only small amounts of rhodanese and 3-mercaptopyruvate sulfurtransferase (Aminlari et al., 2002; Eskandarzade et al., 2012; Nagahara et al., 1999; Shahbazkia et al., 2009) , therefore it is desirable that antidotes against CN rapidly reach the brain. Acute CN intoxication can be treated by available antidotes (Petrikovics et al., 2015) such as Nithiodote (comprised of a combination of sodium thiosulfate and sodium nitrite) (Scottsdale, 2011) and Cyanokit (hydroxocobalamin) (Borron et al., 2006; Zakharov et al., 2015) . The fact that these antidotes require intravenous administration limits their application in mass casualty scenarios (Maraffa et al., 2012) . Each component also has specific limitations. The primary limitation of Cyanokit is that it requires a high injection volume (>200 ml). The major limitation of sodium nitrite is the formation of excess methemoglobin in certain individuals even at the recommended doses, resulting in methemoglobinemia (Klimmek et al., 1988) . The antidotal activity of sodium thiosulfate has limitations due to its small volume of distribution, short biological half-life and high rhodanese dependence (Schulz, 1984; Way et al., 1988) .
The novel CN countermeasure dimethyl trisulfide (DMTS) showed remarkable antiCN effects in vitro and in vivo (Kovacs et al., 2016a,b; Rockwood et al., 2016) . Comparing the sulfur donor efficacy of DMTS to sodium thiosulfate, the sulfur donor component of Nithiodote, DMTS was 3 times more effective than thiosulfate in vivo. It also converts CN to thiocyanate 40 times faster than thiosulfate in vitro (Rockwood et al., 2016) . These results indicate that DMTS is a promising agent against CN intoxication. As a highly lipophilic molecule, DMTS has low solubility in water and thus requires thoughtful formulation to obtain concentrations that are suitable for intramuscular administration. Such formulations have the potential for use in self-administration kits for mass casualty scenarios. A lipid based formulation was developed, when DMTS was encapsulated into micelles and tested in vitro and in vivo, but the encapsulation efficacy of the product was not satisfying (Kovacs et al., 2016a) . Various co-solvents and surfactants were tested for DMTS formulation (Kovacs et al., 2016b) . Polysorbate 80 (Poly80) at 15% (w/v) and 20% (w/v) resulted the best solubilizing properties for DMTS and was further tested in vivo in mice (Kovacs et al., 2016b) . The 15% (w/v) Poly80 formulated DMTS provided over 3 times LD50 (Lethal Dose, 50%) protection at the DMTS dose of 100 mg/kg when the LD50 values were determined by the up-and-down method (Bruce, 1985) in a mouse model. The antidotal protection was expressed as an antidotal potency ratio (LD50 of CN with the antidote divided by the LD50 of CN without antidote). Protection of the brain depends upon the ability of the CN antidote to cross the blood-brain barrier (BBB) and efficiently reach the brain. The BBB can hinder drug penetration by cellular membranes, by tight intercellular junctions, by active cellular efflux pumps, and by the high metabolic activity of BBB cells. Based on the 5 simple rules recommended by Clark (2003) , DMTS would be expected to passively penetrate through the cellular membranes of the BBB, because: (1) it has no nitrogen or oxygen, (2) it has a range of predicted logP values (1.94-2.93) that is greater than zero (NCBI CID 19310, CSID:18219, http , (4) a molecular weight (126.25) below 450, and (5) a predicted logD (¼logP for a neutral compound) value between 1 and 3. The prediction that DMTS will passively penetrate the BBB is promising. To the best of our knowledge, there have been no prior experimental studies of the permeability of the BBB to DMTS.
In this study, our aim was to test the BBB permeability and the in vivo pharmacokinetics of DMTS in blood and brain. For permeability tests, two in vitro models of the BBB were applied: (1) parallel artificial membrane permeability assay (PAMPA) and (2) brain endothelial cells co-cultured with pericytes and astrocytes. The effects of DMTS on cellular viability and on tight junctions were investigated. Furthermore, the pharmacokinetic profile in blood and brain for DMTS was determined in a mouse model.
MATERIALS AND METHODS

Chemicals
All chemicals were of the highest purity commercially available. HPLC grade from J.T. Baker (Center Valley, Pennsylvania), HPLC grade acetonitrile and ethanol from Acros (Thermo Fisher Scientific, Geel, Belgium), Poly80 from Alfa Aesar (Ward Hill, Massachusetts), DMTS, dimethyl disulfide (DMDS), sodium heparin from Sigma-Aldrich (St Louis, Missouri) and dibutyl disulfide (DBDS) from TCI America (Portland, Oregon) were purchased. Hamilton gas tight luer-lock syringes (100 ml), micro centrifuge tubes (1.7 ml), screw cap vials (2 ml and 5 ml) and needles (27 G Â 1 =2) from VWR International (Radnor, Pennsylvania) and inserts (250 ml) with polymer feet were purchased from Agilent Technologies (Santa Clara, California). A 10 U/ml heparin solution was prepared by diluting a 10 000 U/ml heparin stock solution with 0.9% (w/v) saline solution. Aqueous Poly80 solutions were used at 5 and 15% (w/v) concentrations. The DMTS stock solution (50 mg/ml) used for the in vivo studies was made by dissolving DMTS in 15% (w/v) Poly80, and another DMTS stock solution (10 mg/ml) used for the BBB-PAMPA and the cell culture was prepared in 5% (w/v) Poly80. Acetonitrile was used to prepare the 0.1 mg/ml DMDS solution, and ethanol for the 1 mg/ml DBDS solution. A 20 millimolar verapamil stock solution was prepared in DMSO (Sigma Aldrich, St. Louis, Missouri). Ringer-HEPES (R-H) buffer was prepared by dissolving the components in distilled water resulting in the final concentrations of 150 mM for NaCl, 2.2 mM for CaCl 2 , 0.2 mM for MgCl 2 , 5.2 mM for KCl, 5 mM for HEPES, 6 mM for NaHCO 3 , 3.3 mM for glucose. Poly80 (0.05% w/v) in Prisma HT and R-H buffer was used in the BBB-PAMPA experiment and for the cell culture studies, respectively.
Testing DMTS Permeability in the BBB-PAMPA System A BBB-PAMPA system was applied to model the passive permeability properties of the BBB, and to provide an in vitro method for testing the diffusion of DMTS through the BBB (Di et al., 2003) . Prisma HT buffer was used as a solvent in the donor compartment in the BBB-PAMPA. According to the manufacturer's instruction, 6.25 ml of Prisma HT concentrate (PN 110151, pION, Billerica, Massachusetts) diluted with HPLC purity water to 250 ml and the pH was set to 7.4 by 0.5 M NaOH. The stock solution of 10 mg/ml DMTS in 5% (w/v) Poly80 was diluted 100-fold with Prisma HT buffer to get the working solution of 0.1 mg/ml DMTS in 0.05% (w/v) Poly80. Verapamil (pION) was used as a control for the BBB-PAMPA experiments. The permeability profile of verapamil is known from the literature (Mensch et al., 2010) . To test and exclude the effect of Poly80 on DMTS permeability, verapamil was used with and without Poly80. Two verapamil solutions with a concentration of 200 mM were prepared in Prisma HT buffer, one with 0.05% (w/v) Poly80 and one without Poly80. Brain Sink Buffer (PN110674, pION) with or without 0.05% (w/v) Poly80 was used in the acceptor compartment. The arrangement of the solutions in the donor and acceptor phases is shown in Table 1 .
Before loading the solutions into the PAMPA plates, the concentrations of DMTS and verapamil were analyzed, respectively, by HPLC and UV spectrophotometer. The bottom 96-well microplates (PN120551, pION) with magnetic discs served as the donor compartment for the BBB-PAMPA permeability experiments. The wells of the plates were filled with 180 ml of 0.1 mg/ml DMTS in 0.05% (w/v) Poly80, 200 mM verapamil with or without 0.05% (w/v) Poly80 (Table 1 ). The BBB-PAMPA membranes on the acceptor plate (pION) were impregnated with 5 ml of BBB lipid cocktail (pION, PN 110672) . The donor and acceptor plates were carefully mounted (PAMPA sandwich) to prevent any bubble formation between the compartments. The acceptor wells were filled with 200 ml Brain Sink Buffer with or without 0.05% (w/v) Poly80 (Table 1 ). The mounted plates were placed on the PAMPA plate stirrer (Gut-Box, pION) and the donor phase was stirred with 40 mm Aqueous Boundary Layer. The DMTS samples from the acceptor phase were collected at 30 and 60 min. The DMTS and verapamil samples were collected from the donor and acceptor phases after 90-min incubation (Table 1) . HPLC-UV was used for analyzing the DMTS samples and UV spectrophotometer for the verapamil samples. For each treatment group 5-10 replicates were measured. The clearance volume was calculated for DMTS at 30, 60, 90 min and the apparent permeability was derived from the line fit to the clearance data (Supplementary Material) (Kiss et al., 2014) . For verapamil the apparent permeability was calculated as described previously (Kiss et al., 2014, Supplementary Material) .
Cell Culture Conditions-BBB Model Construction Primary cultures of rat brain endothelial cells, glia and pericytes were used in the construction of the in vitro BBB model as described previously (Nakagawa et al., 2009; Veszelka et al., 2013) . Endothelial cells and pericytes were isolated from 3-week-old Wistar rats. Mixed glial cultures (containing 90% astrocytes) were isolated from neonatal Wistar rats. The detailed isolation procedure was published by Nakagawa et al. (2009) . For the cell culture studies, all reagents were purchased from SigmaAldrich Kft., Hungary, unless otherwise indicated. Brain endothelial cells were cultured in DMEM F-12 (Gibco, Life Technologies, Carlsbad, California) supplemented with 15% plasma-derived bovine serum (First Link, UK), 100 mg/ml heparin, 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml sodium selenite, 1 ng/ml basic fibroblast growth factor (Roche, Switzerland) and 50 mg/ml gentamycin. For the establishment of the BBB model, brain microvascular pericytes were passaged to the bottom side of 12-well tissue culture inserts (Transwell, polycarbonate membrane, 0.4 mm pore size, Corning Costar, USA) coated with collagen IV at a density of 1.5 Â 10 4 cells/cm 2 . After attachment of the pericytes, brain endothelial cells (8 Â 10 4 cells/cm 2 ) were seeded to the upper side of the fibronectin and collagen IV coated membranes. Primary cultures of rat glial cells were passaged to the bottom of 12-well dishes (Corning, Costar, New York) coated with 100 mg/ml collagen type IV in sterile distilled water and cultured for 2 weeks before using for the triple coculture model. Pericytes and glial cells were cultured in DMEM/ HAM's F-12 supplemented with 10% fetal bovine serum (PanBiotech GmbH) and 50 mg/ml gentamycin. To construct the in vitro BBB co-culture model, Transwell culture inserts were placed into 12-well plates containing glial cells with endothelial culture medium in both compartments. After 2 days of coculture leading to the formation of a confluent monolayer of brain endothelial cells, 550 nM hydrocortisone was added to the culture medium to tighten junctions (Deli et al., 2005; Walter et al., 2015) .
Cellular Viability-MTT Dye Conversion Assay
For the cell viability assay, the isolated rat brain primary endothelial cells were seeded to 96-well plates at a density of 6 Â 10 3 cells/well and cultured for 3-5 days until confluency (Kiss et al., 2013) . To test the dose-dependent toxicity of DMTS, the monolayers were treated with DMTS solution in the concentration range of 1-300 lg/ml in 0.05% (w/v) Poly80 and phenol red free DMEM (Life Technologies, Gibco, Carlsbad, CA, USA) for 10 min. Cells which received only culture medium served as a negative control group (100% viability), while cells treated with 1 mg/ml Triton X-100 detergent served as a positive control (100% toxicity). The viability of cells treated with DMTS was compared with these positive and negative controls. After the 10-min incubation time, the DMTS containing treatment medium was removed, the cells were washed with phosphate buffer saline (PBS) and 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) containing fresh medium was added to the culture and kept for 3 h in a CO 2 incubator. The conversion rate of the yellow MTT dye to the purple formazan reflects the metabolic activity of the cells. The formazan crystals were dissolved in DMSO and the amount of the converted dye was determined by measuring absorbance at 595 nm in a microplate reader (Fluostar Optima, BMG Labtechnologies, Ortenberg, Germany). The cell metabolic activity (viability) was calculated as a percentage of the dye conversion by the non-treated cells.
Integrity of the Paracellular Barrier
Transendothelial electrical resistance (TEER) measurements were used to determine the tightness of the intercellular junctions in the BBB model (Deli et al., 2005) . TEER measurements were made by an EVOM Volt/Ohm Meter (World Precision Instruments, USA) combined with STX-2 electrodes and expressed relative to the surface area of the monolayers (X Â cm 2 ). The resistance of cell-free inserts (130 X Â cm 2 ) was subtracted from the measured values. The BBB model showed a The donor compartments and the corresponding acceptor compartments are placed in the same row.
TEER value of 386 6 67 X Â cm 2 indicating the tight barrier properties necessary for the permeability assay.
Permeability Experiments on the BBB Culture Model
For permeability studies in cell culture, a DMTS working concentration of 0.1 mg/ml was selected. This concentration was approximately 100 times higher than the detection limit in R-H buffer (1.4 mg/ml) and was still non-toxic to the cells. In contrast to that used in the PAMPA system, the membranes used in the culture BBB model are thin (10 mm) and highly permeable; therefore, the log phase is negligible for a lipophilic compound, like DMTS. Based on these characteristics, and to limit any potential effect of cellular metabolism of DMTS, a short time period of 10 min was employed for the measurement of P app in culture BBB experiments. Inserts were transferred to 12-well plates containing 1.5 ml R-H buffer in the acceptor (abluminal) compartments. Culture medium was replaced in the donor (luminal) compartment with freshly prepared 0.1 mg/ml DMTS solution containing 0.05% (w/v) Poly80. After a 10-min incubation on a horizontal shaker, solutions from both compartments were collected and prepared for HPLC measurement. DMTS concentrations from the luminal and abluminal compartments were determined by HPLC-UV. After the penetration assay, the integrity of the brain endothelial barrier was verified by measuring the permeability of the marker molecule fluorescein (Mw: 376 Da; 10 lg/ml final concentration in R-H buffer). The assay with fluorescein was 15 min long. Concentrations of fluorescein in samples were determined by a fluorescence microplate reader (Fluostar Optima, BMG Labtechnologies, Germany; excitation wavelength: 485 nm, emission wavelength: 535 nm). The apparent permeability coefficients (P app ) for DMTS and fluorescein and transfer and recovery (mass balance) of DMTS were calculated as described in previous papers (Hellinger et al., 2012; Kiss et al., 2014; Kü rti et al., 2012) .
Immunohistochemistry
Morphological changes in brain endothelial monolayers were followed by immunostaining for junctional proteins claudin-5, zonula occludens protein-1 (ZO-1), and b-catenin. After the transport studies, inserts were washed with PBS and the cells were fixed with 3% paraformaldehyde solution for 30 min at room temperature and incubated in 0.2% TX-100 solution for permeabilization. Non-specific binding sites were blocked with 3% bovine serum albumin in PBS. Cells were incubated with primary antibodies rabbit anti-ZO-1, rabbit anti- 
Pharmacokinetics of DMTS in Mouse Blood and Brain
For the absorption kinetics experiment, the DMTS concentration in blood and brain was measured from samples taken 0, 5, 10, 20, 60 and 120 min after intramuscular injection. DMTS stock solution at 50 mg/ml concentration was prepared by dissolving DMTS in 15% (w/v) Poly80 solution (Petrikovics and Kovacs, 2016) . A 200 mg/kg DMTS dose was applied by injecting the DMTS stock solution intramuscularly. The injection volume (approximately 90-110 ml) was halved and both rear legs were injected. For the control mouse, the 15% (w/v) Poly80 solution without DMTS was injected. The mice were anesthetized by inhalation of isoflurane before the blood and the brain samples were taken. Right after anesthesia blood samples were collected from the heart into heparinized tubes. The rest of the blood was washed out from the circulation by performing cardiac perfusion with approximately 8 ml physiological saline containing 10 U/ml heparin under the deep terminal anesthesia. The brain was quickly removed from the skull and divided into 2 parts. The measurement of the DMTS concentrations in the blood and brain samples was initiated immediately following collection to minimize the effect of any post collection reactions of DMTS with the sample (Kiss et al., 2017) . The volume of distribution and the tissue partitioning coefficient (Kp brain:blood ) for DMTS were calculated (Supplementary Material).
Preparation of DMTS Samples for HPLC Analysis DMTS samples originated from the BBB-PAMPA measurements. The DMTS concentrations from the R-H solutions in the BBB-PAMPA system were determined by HPLC-UV. A 60 ml aliquot of internal standard solution (0.05 mg/ml DMDS in acetonitrile) was transferred to 250 ml glass inserts within the HPLC glass vials (Agilent Technologies), and 40 ml of the BBB-PAMPA DMTS samples were added to each insert. The vials were hand-vortexed for 10 s, followed by auto-vortexing for 5 min at room temperature, and loaded into the HPLC instrument for measurement.
DMTS samples collected from the cell culture measurements. A 300 ml aliquot of internal standard solution (0.05 mg/ml DMDS in acetonitrile) was mixed with 200 ml of the DMTS containing samples. The solutions were hand-vortexed for 10 s, auto-vortexed for 5 min at room temperature, and centrifuged for 5 min at 4 C with 14 000 RCF. The supernatant (150 ml) was transferred to 250 ml glass inserts in the HPLC glass vials, and loaded into HPLC instrument for measurement.
Blood samples containing DMTS collected from animals. The method developed for DMTS detection from blood was applied in this study (Kiss et al., 2017) . Briefly, immediately after collection of the DMTS-exposed blood (80 ml), 200 ml of the internal standard (0.1 mg/ml DMDS) in ice cold acetonitrile was added. Then the microcentrifuge tubes with the solutions were hand-vortexed for 10 s, autovortexed for 10 min at room temperature, and centrifuged for 5 min at 4 C, and 14 000 RCF. The supernatants (80 ml) were transferred to 250 ml glass inserts in the HPLC glass vials, and loaded into HPLC instrument for measurement.
DMTS Analysis by HPLC-UV
A Dionex Ultimate 3000 (Thermo Scientific, Waltham, Massachusetts) HPLC-UV instrument was used in the analysis (Kiss et al., 2017) . Forty microliters of DMTS containing samples were injected onto a guard column connected to a 250 Â 4.60 mm nonpolar C-8 analytical column having a Phenomenex Luna stationary phase (consisting of bonded octane units coated on silica support particles, pore size of 100 Å , outer diameter of 5 mm). Isocratic elution was employed. A 35:65 v/v mixture of water and acetonitrile flowing at rate of 1 ml/min served as the mobile phase. The column backpressures ranged from 1430 to 1450 psi. The analyte absorbance at 215 nm was monitored by a UV detector. The calibration curve used for BBB-PAMPA and cell culture studies is shown in Figure 1 . The intraand inter-day precisions varied from 1.1 to 10.2 CV% (relative standard deviation), while intra-and interday accuracies varied from À13.2 to þ 0.9% in the BBB-PAMPA system. This HPLC-UV method was also used for experiments with blood, where the limit of detection (LOD) and limit of quantification (LOQ) were 1.46 and 4.45 mg/ml, respectively. Furthermore, the intra-and interday precisions varied from 6.9 to 12.2 CV% (relative standard deviation), while the intra-and inter-day accuracies varied from À14.8% to À3.7% (Kiss et al., 2017) .
DMTS Analysis by GC-MS
GC-MS was used to measure DMTS concentration from the brain samples with a previously developed method (Kiss et al., 2017) . To every 220-mg mouse brain tissue 1 ml ethanol was added. The brains were homogenized by a Precellys 24 tissue homogenizor (Bertin Technologies, Montigny-le-Bretonneux (France), Precellys vials with 1.4 mm ceramic beads, 6500 RPM, 3 times 1 min). The brain homogenate (475 ml) was added to 25 ml of 1 mg/ml DBDS (in ethanol) solution. A magnet bar was placed into the vials and the sample was stirred for 5 min. PDMS fiber (Agilent Technologies) was inserted into the headspace of the vials and were incubated for 10 min. To detect the molecules from the fiber GC-MS was used. For sample analysis an Agilent Model 6890 A gas chromatograph and Agilent Model 5973 C mass selective detector was used. The GC column was an Concentrations were determined by the calibration curve published earlier, and the LOD and LOQ were determined to be 213 and 645 ng DMTS/g brain, respectively (Kiss et al., 2017) . The intra-and interday precisions were below 24.3 CV %, while the accuracy was between À1.3% and þ2.4%.
UV Spectrophotometric Method for Verapamil Analysis
Samples containing verapamil were collected from the BBB-PAMPA measurements. To the micro-centrifuge tubes filled with 300 ml of 200 mg/ml DMSO in water, 140 ml of the collected samples were added. After vortexing 400 ml of the mixture was transferred to a narrow quartz cuvette (VWR). Absorbances were measured in the range of 210-400 nm by a Shimadzu UV2101 (Shimadzu Corp., Kyoto, Japan) spectrophotometer. The absorbances measured at 278 nm were used for the calculation.
Statistical Analysis
All plotted values represent the means 6 SD. Unpooled Student t-tests were used to assess the significance of changes in the permeabilities of verapamil in the presence and absence of Poly80. To evaluate the toxic effect of DMTS on endothelial cells 1-way ANOVA followed by Dunnett's test (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, California) was used. The effect of the variable under study was considered statistically significant, if the random probability (p) of the observed change in signal associated with a specific treatment was < .05. The number of replicate samples varied from 3 to 10.
RESULTS
Permeability of DMTS in the BBB-PAMPA System
The BBB-PAMPA system is a widely used surrogate model of BBB permeability, therefore the passive penetration of DMTS was tested on it (Di et al., 2003 (Di et al., , 2009 Mensch et al., 2010; Mü ller et al., 2015) . The clearance volume of DMTS was determined at 30, 60, and 120 min after injection and the permeability was calculated from the data shown in Figure 2A . In the BBB-PAMPA system the P app of DMTS in the presence of 0.05% (w/v) Poly80 was 11.8 Â 10 À6 cm/s. A lag time of 6.41 min in DMTS appearance in the acceptor compartment was measured. Verapamil, used as control, showed a P app of 25.7 Â 10 À6 cm/s in the absence of Poly80 ( Figure 2B ). In the presence of 0.05% (w/v) Poly80, the permeability of verapamil decreased by 16%, to 21.5 Â 10 À6 cm/s.
Effect of DMTS on Viability of Cultured Brain Endothelial Cells
The viability of brain endothelial cells in the presence of DMTS at different concentrations was tested by the MTT dye conversion assay (Figure 3) . A 10-min treatment with DMTS in a concentration range of 1-300 mg/ml did not significantly decrease the viability compared with the non-treated control group. However, at the concentrations of 30, 100, and 300 mg/ml DMTS enhanced the metabolic activity of the cells. Triton X-100 was the positive control for cell death and resulted in complete toxicity within 10 min. Permeability of DMTS Through the Triple Co-Culture Model of BBB A very high permeability was measured for DMTS in the BBB culture model (158 6 14 Â 10 À6 cm/s) indicating a complete distribution between the 2 compartments ( Table 2 ). The permeability of DMTS in the cell free inserts (159 6 7 Â 10 À6 cm/s) was similar to those measured with cell culture. The 70% recovery of the highly lipophilic DMTS is in good accordance with the recovery of more than 100 tested compounds on BBB culture models in our previous study (Hellinger et al., 2012) . The passive paracellular permeability of hydrophilic fluorescein through the cellular barrier remained low (P app : 4.1 6 0.9 Â 10 À6 cm/s) following a 10-min DMTS treatment, indicating that the barrier integrity was not compromised by DMTS treatment. The DMTS permeability was approximately 40 times higher than that of fluorescein.
Effect of DMTS on Cell Junctions
Following the transport experiments, the cells on the inserts were stained for junctional proteins. ZO-1 and b-catenin stainings show that the monolayer integrity is not disturbed in agreement with the fluorescein permeability values (Figure 4) . The cellular distribution of claudin-5 was slightly changed, with more cytoplasmic staining. The living cell nuclei were stained with both cell impermeable ethidium homodimer-1 and cell permeable Hoechst dye 33342. No labeling of nuclei with ethidium homodimer-1 was observed, denoting intact cell membranes after the DMTS treatment. The untreated cells showed similar morphology following each immunostaining treatment. Data are presented as mean 6 SD (n ¼ 10). B, Apparent permeability of verapamil combined with Poly80, and verapamil alone. Data are presented as mean 6 SD (n ¼ 5).
Significance analysis was performed using unpaired Student t test: statistically significant difference was detected between verapamil þ Poly80 and verapamil permeability (*p < 0.05). 
Pharmacokinetics of DMTS
The pharmacokinetics of DMTS was investigated in vivo in blood and brain (Figs. 5A and 5B). The concentrations of DMTS were determined at time intervals of 0, 5, 10, 20, 60, and 120 min after the intramuscular injection of 200 mg/kg dose of DMTS using previously developed methodology (Kiss et al., 2017) . A comparison of the first 3 time points in Figures 5A and 5B, shows that DMTS uptake into the blood is largely complete by 5 min, while uptake into the brain is still climbing strongly between the 5 and 10 min sampling points. For both samples, uptake is rapid, and c max is achieved in <10 min in blood, and very close to 10 min in the brain. The volume of distribution (V D ) of DMTS was calculated after 10 min treatment, where the c max was measured in blood, and resulted 0.21 6 0.03 L. The tissue partitioning coefficient for brain (Kp brain:blood ) was 0.0179 (1.79%).
DISCUSSION
These studies focus on the BBB permeability and pharmacokinetics of the promising CN antidote candidate DMTS. To the best of our knowledge this is the first publication investigating the absorption of DMTS into blood, the in vitro BBB permeability and the in vivo distribution in the brain. The penetrability of DMTS through the BBB was measured in a BBB-PAMPA system and in a cell culture model of the BBB. Both of these systems are widely used by pharmaceutical companies to screen the permeability profile of drug candidates (Di et al., 2009; Hellinger et al., 2012; Helms et al., 2016; Mensch et al., 2010) . Compound lipophilicity is an important physicochemical property, which impacts: penetration to the central nervous system, partitioning into other organs, membrane permeability and binding to plasma proteins (Lipinski et al., 2001) . The logarithm of the octanol/water partitioning coefficient (logP) provides a measure of the lipophilicity of a molecule. Verapamil was used as a high permeability standard in BBB-PAMPA experiments. The experimentally measured logP for verapamil is 3.79 (DB00661,https://www.drugbank.ca/drugs/DB00661. Accessed 20:33, September 15, 2017). The predicted logP for DMTS ranges from 1.94 to 2.93 (NCBI CID 19310, CSID: 18219, http:// www.chemspider.com/Chemical-Structure.18219.html. Accessed September 15, 2017) . The measured logP for verapamil and the predicted logP values for DMTS are large enough to predict that both compounds will have high permeability in the BBB-PAMPA system. Our permeability result with verapamil (25.7 Â 10 À6 cm/s) as a control in the BBB-PAMPA is comparable with the literature data (16.0 Â 10 À6 cm/s; 18.5 Â 10 À6 cm/s; 23.7 Â 10 À6 cm/s; Cahlikova et al., 2015; Di et al., 2003; Mensch et al., 2010) . The presence of Poly80 was required to achieve sufficiently high concentrations of DMTS. Due to its surfactant properties Poly80 may indirectly influence the lipid membrane permeability in BBB-PAMPA. To check its effect on the lipid membranes, a verapamil control was applied in the system with and without Poly80. One would expect a permeability enhancement effect for verapamil in the presence of Poly80 due to its absorption enhancer properties (Kiss et al., 2014; Rege et al., 2002) . However, a slight decrease in the permeability of verapamil through the BBB-PAMPA model was observed in the presence of 0.05% (w/v) Poly80 ( Figure 2B ). This decrease in permeability may be due to the association between the Poly80 and the BBB-PAMPA membrane. This effect is not expected to be significant in vivo, because (1) Poly80 will be diluted upon entering the circulation and will have many competing opportunities to partition out of blood into tissues before reaching the BBB; (2) earlier studies demonstrated that Poly80 at 0.1% (w/v) (1 mg/ml) did not cause any cell damage after 1 h in Caco-2 and RPMI 2650 cell culture (Kiss et al., 2014; Kü rti et al., 2012) .
The in vitro triple co-culture model for the BBB yields permeability measurements for drugs that are generally comparable to those obtained from in vivo data (Nakagawa et al., 2009 ). In our experiments, this culture model was applied to estimate the permeability of DMTS through the BBB. Results showed that the endothelial cell layers did not present a barrier against DMTS as indicated by similar permeability values in culture models and cell-free inserts. The P app of DMTS was similar to that of the highly lipophilic and BBB penetrating drug caffeine on the same model (Hellinger et al., 2012) . The recoveries of DMTS (Table 2) in the culture and in the cell free permeability assays were found to be, respectively, 67.7% and 69.4%. These recoveries were calculated as mass balances (Hubatsch et al., 2007) , and indicate, respectively, 32.3% and 30.6% losses of DMTS. Since recoveries were similar in the presence of cells and in the cell free assays, we assume that cellular metabolism was a negligible loss mechanism in these experiments. Based on our unpublished results (manuscript in preparation) a significant amount of the DMTS may attach to the surface of glass or plastic. Therefore, we assume that DMTS losses were primarily due to the binding of DMTS to culture insert membranes or to the walls of plastic plates. Based on the high TEER values and the low permeability of fluorescein, the cellular barrier remained intact 10 min after the treatment. Furthermore, proteins building up the tight junctions, ZO-1 and claudin-5, and adherent junctions, b-catenin, showed a typical morphology with strong staining between the neighboring endothelial cells after the DMTS treatment (Figure 4) . Double-nuclei staining was performed after the DMTS permeability measurement to assess membrane damage and cell death (Kiss et al., 2013) . The fact that no staining of ethidium homodimer-1 was observed indicated that endothelial cells were alive and that their membranes were intact. Furthermore, DMTS did not decrease the metabolic activity of the brain endothelial cells at tested concentrations, but even slightly enhanced this activity at higher concentrations as shown by the MTT assay. These data indicate that DMTS can be safely used at 0.1 mg/ml concentration within 10 min in these cell cultures, while the effects of longer exposure to DMTS should be tested in the future.
The permeability of DMTS measured in the BBB culture model (158 Â 10 À6 cm/s) was approximately 13 times higher than in the BBB-PAMPA system (12 Â 10 À6 cm/s). This difference between the permeability values measured in PAMPA and cell culture models can also be observed for other drugs. For example, caffeine and alprazolam have permeabilities of 2.03 Â 10
À6
and 11.12 Â 10 À6 cm/s through the BBB-PAMPA, respectively, and 44.40 Â 10 À6 and 103.63 Â 10 À6 cm/s through the Caco-2 cellular barrier membranes (Mensch et al., 2010) . Caffeine (logP caffeine ¼ À0.07; (NCBI CID 2519) can pass through the cellular barrier with passive and facilitated diffusion (McCall et al., 1982) , while alprazolam (logP alprazolam ¼2.12; NCBI CID 2118) penetrates by passive diffusion and active transport using human organic cation transporter 2 (Chiba et al., 2013) . The significant difference in permeability of DMTS in the BBB-PAMPA-containing only lipids-and the BBB model, which expresses transporters (Walter et al., 2015) suggests that in addition to passive diffusion DMTS may cross the BBB by another facilitated or active transport mechanism. DMTS uptake into the blood and soon thereafter into the brain occurred fast enough to reach the c max within 10 min following intramuscular injection. The toxic effects of CN can appear from a few minutes to an hour after exposure depending upon the concentration. The rapid penetration of a CN antidote is essential to efficiently defend the body in cases of acute intoxication. In the previous paragraph we discussed a possible active transport mechanism of DMTS and the quick and significant penetration into the brain observed in vivo, which together do not contradict the in vitro experimental results. The concentration of DMTS reached the maximum of 25.2 mg/ml in the blood and 1.07 mg DMTS/g in the brain 10 min after the injection. To prevent the biasing effects of blood in the brain experiments, the cerebral blood was flushed out of the brain by cerebral perfusion prior to extracting the brain for analysis. This ensured that the DMTS determination from the brain was not affected by the DMTS in the blood and only the DMTS that entered the brain was analyzed. The disappearance of blood from brain tissue during perfusion can easily be observed. The volume of distribution for DMTS showed a higher value than the mouse total body water (approximately 14.5 ml; Davies and Morris, 1993) . This high V D is typical for lipophilic drugs, and may indicate a greater amount of tissue distribution.
Detailed studies of the mechanisms of DMTS penetration through BBB were beyond the scope of this work. DMTS may also undergo chemical transformations in the brain, as it appears to happen in the blood (Kiss et al., 2017) . Ongoing efforts in our lab are focused on the investigation of these interactions between the DMTS and the blood or the brain and will be published separately.
Our results with DMTS showed better pharmacokinetic parameters than the commercially available CN antidotes, thiosulfate and hydroxocobalamin. Thiosulfate, the sulfur donor component of Nithiodote, has limited ability to cross the BBB (Pollay and Kaplan, 1971; Neuwelt et al., 1998) and has a shorter half-life (15-20 min; Schulz, 1984 ; DB09499,https://www.drug bank.ca/drugs/DB09499. Accessed 20:33, September 15, 2017) in the blood than DMTS. The half-life of DMTS in blood is 36 min (De Silva et al., 2016) and it can effectively cross the BBB as the results of this article proved. Van den Berg et al. (2003) measured the concentration of hydroxocobalamin (component of Cyanokit) in the cerebrospinal fluid (CSF) and plasma after intranasal or intravenous administration. In this work, the partition coefficient of DMTS from the blood to the brain (Kp brain:blood ¼ 1.79%) was found to be approximately 3 times higher than the previously reported partition coefficient of hydroxocobalamin from the blood plasma to the CSF (Kp CSF:plasma ¼ 0.5%-0.6%). Furthermore, the reported 30 min delay between plasma absorption and CSF uptake of hydroxocobalamin (Van den Berg et al., 2003) , was longer than the 10 min delay, found in these experiments, between DMTS IM administration and c max in the brain.
CONCLUSION
The permeability of DMTS through the BBB was measured in a BBB-PAMPA system and in a cell culture BBB model. The high penetrability of DMTS through the BBB-PAMPA indicates that the rate of passive diffusion is significant. The 13 times greater penetrability of DMTS through the BBB cell culture model suggests the presence of an active transport mechanism for DMTS in the BBB of living systems. The results of the pharmacokinetics investigations in a mouse model (blood and brain) were consistent with those of the in vitro experiments. The DMTS reached a peak brain concentration in live mice within 10 min following intramuscular injection. These permeability and pharmacokinetic results highlight the promise of DMTS as a brain protective antidote. Together with the prior observations of high in vivo antidotal efficacy against CN, these results highlight the potential of DMTS as a candidate for future clinical studies.
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